Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.13 - $6.79 $425,398 - $699,383
103,002 New
103,002 $636,000
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $575,040 - $781,731
115,470 Added 122.27%
209,905 $1.26 Million
Q3 2023

Nov 15, 2023

BUY
$6.71 - $7.92 $119,256 - $140,762
17,773 Added 23.18%
94,435 $668,000
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $533,567 - $675,392
76,662 New
76,662 $539,000
Q3 2022

Nov 14, 2022

BUY
$10.79 - $14.81 $742,546 - $1.02 Million
68,818 Added 286.01%
92,879 $1.17 Million
Q2 2022

Aug 15, 2022

BUY
$7.89 - $17.88 $189,841 - $430,210
24,061 New
24,061 $255,000
Q4 2021

Feb 14, 2022

SELL
$11.18 - $15.46 $1.47 Million - $2.03 Million
-131,066 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$14.21 - $17.65 $968,667 - $1.2 Million
68,168 Added 108.38%
131,066 $1.88 Million
Q2 2021

Aug 16, 2021

BUY
$9.5 - $17.24 $47,319 - $85,872
4,981 Added 8.6%
62,898 $994,000
Q1 2021

May 17, 2021

BUY
$7.37 - $13.61 $426,848 - $788,250
57,917 New
57,917 $589,000
Q2 2020

Aug 14, 2020

SELL
$1.9 - $5.61 $93,293 - $275,462
-49,102 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$1.6 - $4.11 $166,408 - $427,460
-104,005 Reduced 67.93%
49,102 $98,000
Q4 2019

Feb 14, 2020

BUY
$1.59 - $3.45 $149,394 - $324,158
93,959 Added 158.85%
153,107 $528,000
Q3 2019

Nov 14, 2019

BUY
$2.5 - $3.73 $55,702 - $83,108
22,281 Added 60.44%
59,148 $169,000
Q2 2019

Aug 14, 2019

BUY
$2.91 - $9.15 $107,282 - $337,333
36,867 New
36,867 $140,000
Q4 2017

Feb 14, 2018

SELL
$4.16 - $5.33 $426,375 - $546,293
-102,494 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$4.1 - $5.97 $420,225 - $611,889
102,494
102,494 $537,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.39B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.